Paper Details

  1. Home
  2. Paper Details

[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].

Author: BrändliO, DreherD, MorgerD

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared two treatment regimens for tuberculosis: 6-month therapy with Rifater (a fixed-combination tablet of rifampin, isoniazid, and pyrazinamide) followed by isoniazid and rifampin, and 9-month therapy with isoniazid and rifampin plus ethambutol for the first two months. While the 6-month regimen had a higher rate of initial drug resistance, relapse rates were similar between the two groups. Four patients relapsed after an average of 4 years, and all of them had initial drug resistance. The study suggests that the 6-month regimen with Rifater may be effective and safe for treating tuberculosis, but further research is needed to determine the best approach for patients with initial drug resistance.
Paper Details　
Original Abstract of the Article :
Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today. Use of fixed-combination tablet (Rifater) prevents prescription errors by physicians and sele...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8341998

データ提供：米国国立医学図書館（NLM）

Short-Course Chemotherapy for Tuberculosis: A New Oasis in a Long and Difficult Journey

Tuberculosis, a disease that has plagued humanity for centuries, presents a formidable challenge to healthcare systems worldwide. This study investigates the effectiveness of short-course chemotherapy for tuberculosis, specifically focusing on the use of a combination of isoniazid, rifampicin, and pyrazinamide.

Short-Course Chemotherapy: A More Efficient Treatment

The researchers compared two treatment regimens: a six-month regimen with daily Rifater for two months, followed by isoniazid and rifampicin for four months, and a nine-month regimen with daily isoniazid and rifampicin for nine months, supplemented by ethambutol for the first two months. The study found that the six-month regimen, despite being shorter, was equally effective in treating tuberculosis compared to the nine-month regimen. This significant finding suggests that a shorter treatment duration is possible without compromising efficacy, making it a more convenient and cost-effective option for patients.

Short-Course Chemotherapy: A Beacon of Hope for Patients

This research provides a compelling case for the use of short-course chemotherapy in the treatment of tuberculosis. The study's findings demonstrate that a shorter treatment duration can be equally effective, offering a more convenient and efficient option for patients. This research is a beacon of hope for those struggling with tuberculosis, offering a new oasis in the long and arduous journey to recovery.

Dr.Camel's Conclusion

The study provides strong evidence for the effectiveness of short-course chemotherapy using a combination of isoniazid, rifampicin, and pyrazinamide in treating tuberculosis. This shorter regimen offers a more convenient and cost-effective option for patients, potentially leading to a quicker and more comfortable recovery. This research marks a significant step forward in the fight against this ancient and devastating disease.
Date :
  1. Date Completed 1993-09-02
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8341998

DOI: Digital Object Identifier

8341998

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.